Oxidative stress and genetics in the pathogenesis of parkinson's disease

Neurobiology of Disease

Volumn 7, Issue 4, 2000, Pages 240-250

  Zhang, Yi ^a   Dawson, Valina L ^a   Dawson, Ted M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Neurodegeneration; Parkin; Parkinson's disease; Reactive oxygen species; Substantia nigra pars compacta; Synuclein

Indexed keywords

HUMAN; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0033825627     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2000.0319     Document Type: Review

References (121)

1. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease
2. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
3. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores
4. Peroxynitrite versus hydroxyl radical: The role of nitric oxide in superoxide-dependent cerebral injury
5. Poly(ADP-ribose) in the cellular response to DNA damage
6. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography
7. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease
8. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
9. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
10. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
11. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
12. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice
13. The role of peroxynitrite in nitric oxide-mediated toxicity
14. New animal models for Parkinson's disease
15. Poly(ADP-ribose) polymerase: A molecular nick-sensor
16. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
17. Lipid peroxidation as cause of nigral cell death in Parkinson's disease
18. Decreased ferritin levels in brain in Parkinson's disease
19. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
20. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group
21. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
22. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dement a with Lewy bodies cases
23. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
24. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions
25. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor
26. A Drosophila model of Parkinson's disease
27. Alpha-synuclein and Parkinson's disease: Selective neuro-degenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo
28. Astrocytes and Parkinsor's disease
29. Similarities and differences between MPTP-induced parkinson-sim and Parkinson's disease. Neuropathologic considerations
30. Filaments of Lewy bodies contain insoluble cytoskeletal elements
31. Pathobiology of the Lewy body
32. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
33. A susceptibility locus for Parkinson's disease maps to chromosome 2p13
34. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
35. Alpha-Synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining
36. Protein nitration in Parkinson's disease
37. NOS knockouts and neuro-protection
38. A kindred with Parkinson's disease not showing genetic linkage to established loci
39. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons
40. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease
41. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles
42. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro
43. Alpha-synuclein in Lewy body disease and Alzheimer's disease
44. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals
45. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene
46. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
47. Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits
48. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
49. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism
50. Methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice
51. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
52. Iron and ferritin in substantia nigra in Parkinson's disease
53. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
54. Oxidative stress in Parkinson's disease and other neurodegenerative disorders
55. Understanding cell death in Parkinson's disease
56. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
57. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments
58. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
59. Synelfin regulation during the critical period for song learning in normal and isolated juvenile zebra finches
60. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase
61. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
62. Transgenic mice expressing a dominant negative mutant interleukin-1 beta converting enzyme show resistance to MPTP neurotoxicity
63. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
64. Manganese superoxide dismutase overexpression attenuates MPTP toxicity
65. MPTP toxicity: Implications for research in Parkinson's disease
66. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
67. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
68. Parkinson's disease. First of two parts
69. Parkinson's disease. Second of two parts
70. The etiology of Parkinson's disease with emphasis on the MPTP story
71. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
72. Molecular and biochemical features of poly (ADP-ribose) metabolism
73. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease
74. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
75. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination
76. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases
77. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group
78. Association between early-onset Parkinson's disease and mutations in the parkin gene
79. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
80. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
81. [123I] Beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
82. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
83. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity
84. Genetics of Parkinson's disease
85. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
86. A novel transactivation domain in parkin
87. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
88. Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins
89. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance?
90. Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease
91. Dopaminergic function in familial Parkinson's disease: A clinical and 18F-dopa positron emission tomography study
92. Pathology and biology of the Lewy body
93. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
94. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
95. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
96. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
97. Reply: A new look at the pathogenesis of Parkinson's disease
98. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice
99. The identification of presymptomatic parkinsonism: Clinical and [18F]dopa positron emission tomography studies in an Irish kindred
100. Mitochondria in the etiology and pathogenesis of Parkinson's disease
101. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) in cat and mouse brain
102. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
103. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients
104. Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients
105. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
106. Free radicals, lipid peroxidation, and Parkinson's disease
107. Frontotemporal dementia and Parkinsonism linked to chromosome 17: A new group of tauopathies
108. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
109. Alpha-synuclein in Lewy bodies
110. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion
111. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
112. Processing of MPTP by monoamine oxidases: Implications for molecular toxicology
113. Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia
114. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
115. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD)
116. Synphilin-1 is present in Lewy bodies in Parkinson's disease
117. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy
118. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations
119. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase
120. Maternal inheritance in Parkinson's disease